Vivus Weight-Loss Drug Qnexa Gets 3-Month FDA Review Delay

Vivus Inc. said U.S. regulators delayed their decision date on whether to approve the obesity pill Qnexa by three months to July 17.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.